The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
This creates variability in purity, dosing, and composition
Introduction Due to its effects on endothelium maintenance and blood vessels (reviewed [1,2,3]), we focused on the therapeutic abilities of the stable gastric pentadecapeptide BPC 157 (reviewed [1,2,3,4,5,6,7,8,9,10,11,12,13,14])
Not a single case
Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences
BPC-157 increases actin gene expression while TB-500 organizes actin for cell movement
